Use of a Novel Fibrin Sealant in Total Knee Arthroplasty
| Status: | Completed |
|---|---|
| Conditions: | Arthritis, Osteoarthritis (OA), Hospital |
| Therapuetic Areas: | Rheumatology, Other |
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 4/21/2016 |
| Start Date: | May 2012 |
| End Date: | August 2015 |
Use of a Novel Fibrin Sealant in Total Knee Arthroplasty: A Prospective Randomized Controlled Clinical Trial
Applying a fibrin spray, after knee device implantation, will help in reducing patient blood
loss and decrease the drop in both hemoglobin and hematocrit levels. Also, with decreased
blood loss there should be a reduced need for blood transfusions.
loss and decrease the drop in both hemoglobin and hematocrit levels. Also, with decreased
blood loss there should be a reduced need for blood transfusions.
Study Design
Study design and control methods:
This study is designed as a prospective, randomized, double-blinded controlled clinical
trial to compare the effect of a fibrin spray applied to the surgical wound as compared to
patients not receiving the fibrin spray.
Treatment group:
The subjects will be randomly assigned to the fibrin treatment group or to the control group
at the time of the surgery via the opening of a randomly selected sealed envelope. The
patient and the independent reviewer will be blinded as to which treatment group the patient
is assigned to. This information will be linked to a confidential database for later review
by the principal investigator.
Treatment allocation:
All eligible patients (i.e., meeting inclusion criteria and no exclusion criteria) will be
treated and observed per the research protocol. All patients will maintain the right to
refuse participation and receive a specific treatment of the study if desired.
Trial Population:
The target sample size is 70 patients for both the treatment and control groups (140 total)
with each group split evenly between males and females. There will be one actively enrolling
surgeon (Dr. Brett Levine). The goal is to enroll a total of 140 subjects experiencing joint
pain that warrants a Total knee arthroplasty (TKA). The specific diagnosis for the joint
pain will not direct the subjects' assignment or eligibility at the time of surgery. All 140
patients will be enrolled from the office of the primary investigator (Dr. Brett Levine).
All indications for TKA will be included unless one of the exclusion criteria is met.
Study design and control methods:
This study is designed as a prospective, randomized, double-blinded controlled clinical
trial to compare the effect of a fibrin spray applied to the surgical wound as compared to
patients not receiving the fibrin spray.
Treatment group:
The subjects will be randomly assigned to the fibrin treatment group or to the control group
at the time of the surgery via the opening of a randomly selected sealed envelope. The
patient and the independent reviewer will be blinded as to which treatment group the patient
is assigned to. This information will be linked to a confidential database for later review
by the principal investigator.
Treatment allocation:
All eligible patients (i.e., meeting inclusion criteria and no exclusion criteria) will be
treated and observed per the research protocol. All patients will maintain the right to
refuse participation and receive a specific treatment of the study if desired.
Trial Population:
The target sample size is 70 patients for both the treatment and control groups (140 total)
with each group split evenly between males and females. There will be one actively enrolling
surgeon (Dr. Brett Levine). The goal is to enroll a total of 140 subjects experiencing joint
pain that warrants a Total knee arthroplasty (TKA). The specific diagnosis for the joint
pain will not direct the subjects' assignment or eligibility at the time of surgery. All 140
patients will be enrolled from the office of the primary investigator (Dr. Brett Levine).
All indications for TKA will be included unless one of the exclusion criteria is met.
Inclusion Criteria:
- Patients must be male or female of any race
- Ages 18-80 years old
- Patients must be undergoing an elective, primary knee arthroplasty performed by the
principal investigator
Exclusion Criteria:
- Allergy or intolerance to the study materials
- Surgical intervention during the past month for the treatment of the painful joint or
its underlying etiology
- History of previous surgeries on the affected joint including previous arthroscopy
(open surgeries)
- Women that are pregnant or may become pregnant
- Patient declines to participate
We found this trial at
1
site
Click here to add this to my saved trials
